Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

December 15, 2021

Study Completion Date

December 15, 2021

Conditions
Covid19SARS-CoV InfectionVaccine Adverse Reaction
Interventions
BIOLOGICAL

QazCoVac-P -COVID-19 Subunit Vaccine

QazCoVac-P (Subunit) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan

OTHER

Placebo

The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)

Trial Locations (1)

080409

Research Institute for Biological Safety Problems Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan, Gvardeyskiy

All Listed Sponsors
lead

Research Institute for Biological Safety Problems

OTHER_GOV